Subpotent Oral Solution Prompts Recall of Hypothyroidism Treatment
The use of recalled products may lead to signs and symptoms of hypothyroidism.
Diagnosis & Disease Information
Diabetes Treatment Adlyxin Will No Longer Be Available in the US
A recent posting on the FDA’s Drug Shortages tracker indicates that the product has been discontinued.
Additional Dosing Options of Tirosint-SOL Now Available
Tirosint-SOL is approved for the treatment of hypothyroidism and for pituitary thyrotropin suppression.
FDA Clears Automated Insulin Dosing App for Patients With Type 1 Diabetes
The prescription-only device works with integrated continuous glucose monitors and alternate controller enabled pumps.
Brenzavvy Approved for Adults With Type 2 Diabetes
The approval was based on data from a clinical program that included 23 clinical trials enrolling more than 5000 adults with type 2 diabetes mellitus.
Dexcom G7 Continuous Glucose Monitoring System Gets FDA Clearance
Dexcom G7 offers new features with a 60% smaller, discreet wearable patch.
Empagliflozin Significantly Reduces HbA1c in Children With Type 2 Diabetes
The trial evaluated the efficacy and safety of empagliflozin and linagliptin in 175 patients 10 to less than 18 years of age with type 2 diabetes.
TransCon PTH Gets Priority Review for Hypoparathyroidism
TransCon PTH is an investigational once-daily long-acting prodrug of parathyroid hormone (PTH[1-34]) designed to restore physiologic levels of PTH for 24 hours each day.
Presence of Glass Particles Prompts Recall of Octreotide Acetate Injection
To date, the Company has not received any reports of adverse reactions related to this recall.
NIH Study Compares Four Commonly Used Type 2 Diabetes Medications
The multicenter, randomized, controlled GRADE study was designed to compare the effectiveness of 4 major FDA-approved medications.
- Loading...
Loading...
Loading... 
Loading...